Recent studies have shown that HFpEF comprises half of all heart failure cases. The prevalence of HFpEF has increased over the last 2 decades, associated with an aging population and increasing prevalence of risk factors, such as hypertension and diabetes mellitus. Yet, trials of conventional heart failure medications have been inconclusive in HFpEF and to date, no therapies have proven to reduce mortality in HFpEF patients. Finding appropriate patients for trials can lead to better research and outcomes.
Join us as we explore the following with OM1’s Chief Medical Officer:
- Finding appropriate HFpEF patients for clinical trials
- Estimating size of eligible patient pool through assessment of inclusion and exclusion criteria
- Deriving relevant variables from structured and unstructured data
- Identifying patients at higher risk for outcomes of interest
**Please be advised this webinar is intended for pharmaceutical and medical device companies. Due to the proprietary nature of the content, all registration approval is at the discretion of OM1. Vendors and consultants will not be permitted to attend at this time.